CIRTA 2019 16th International Congress of the Intestinal Rehabilitation & Transplant Association Paris, July 3-6 BOOK OF ABSRACTS Intestinal Rehabilitation & Transplant ASSOCI A T ION Beaujon CIRTA 2019 Book of Abstracts – Table of Content Table of Content ORAL PRESENTATIONS ................................................................................................................. 14 200.4 - Serial Transverse Enteroplasty (STEP) for the Short Gut Syndrome (SGS) Patients with Gut Failure (GF) ........................................................................................................................................................................................ 15 210.4 - Dynamic repopulation, phenotypic evolution and clonal distribution of recipient B cells and plasma cells in graft mucosa associated with rejection after human intestinal transplantation ...................................... 15 220.4 - Results of Medical and Surgical Rehabilitation of Adult Patients with Type III Intestinal Failure in a comprehensive unit: Is it possible to predict intestinal rehabilitation?.................................................................... 16 220.5 - Diagnosis and management of congenital enteropathies: analysis of a large multi-center cohort and the role of Next Generation Sequencing. ....................................................................................................................... 17 220.6 - Effective radiation dose and bone marrow radiation exposure as a result of radiological investigation in a cohort of multivisceral transplant patients ....................................................................................18 220.7 - Human intestinal tissue-resident memory CD8 T cells comprise two transcriptionally distinct populations ..........................................................................................................................................................................18 230.5 - Washington D.C. single-center experience in adult and pediatric intestinal transplantation ............... 19 230.6 - Multivisceral Transplant without an ostomy – 5-year experience ...........................................................20 230.7 - Disease Recurrence After Intestinal and Multivisceral Transplantation ................................................... 21 250.5 - Early Predictors of Enteral Autonomy in Pediatric Intestinal Failure: Development of a Disease Severity Score ...................................................................................................................................................................... 21 250.6 - Results of a Multicentric Retrolective Study of Teduglutide Treatment in Benign Short Bowel Syndrome in Germany ....................................................................................................................................................... 22 250.7 - Impact of donor selection on early graft loss in Intestinal Transplantation. ........................................... 23 260.5 - An algorithm for progress from parenteral nutrition to oral nutrition for adult intestinal transplant recipients ............................................................................................................................................................................. 23 260.6 - Pediatric Home Parenteral Nutrition (Hpn) In France: A National Survey On The Behalf Of The French Pediatric Hpn Network ........................................................................................................................................ 24 260.7 - Effective transitioning of adolescents into adult intestinal transplant services – survey of NITE members .............................................................................................................................................................................. 24 300.5 - Milk fat globule epidermal growth factor-8 (MFG-E8) has site specific effects on intestinal lengthening in neonatal short bowel syndrome, studied in piglets ......................................................................... 25 300.6 - The REVE study, preliminary results. A Monocentric Single-arm study to characterize the long-term safety, efficacy, and pharmacodynamic of GLP-2 analog (Revestive®) in the management of short bowel syndrome pediatric patients on home-parenteral nutrition (HPN).......................................................................... 25 300.7 - Isolated intestinal transplantation: Are we shifting the paradigm? .......................................................... 27 310.5 - Early Intestinal Barrier Dysfunction Early Post Intestinal Transplantation Is Driven by the Absence of Protective Type 3 Innate Lymphoid Cells and the Persistence of Proinflammatory Type 1 Innate Lymphoid Cells ......................................................................................................................................................................................28 1 CIRTA 2019 Book of Abstracts – Table of Content 310.6 - Risks Factors For The Development Of Graft-Versus-Host Disease (Gvhd) After Intestinal And Multivisceral Transplantation ..........................................................................................................................................28 310.7 - Spleen preservation attenuates GVHD in multivisceral transplant recipients. ........................................ 29 320.1 - Changes in gut microbiota and its metabolic activity in pediatric intestinal failure patients receiving long-term parenteral nutrition ........................................................................................................................................ 29 320.2 - Extending the indications of Intestinal transplantation. Cytoreduction and modified multivisceral transplantation for patients with end-stage pseudomyxoma peritoneii. .............................................................. 30 320.3 - Ultra-Short Bowel Syndrome (USBS) – Does the lengthening procedures improve the outcomes? Intestinal Rehabilitation Program (IRP) Children’s National Medical Center (CNMC) Washington DC - USA 31 320.4 - Use of Arterial Embolisation to Facilitate Exenteration during Multi-visceral and Intestinal Transplantation ................................................................................................................................................................... 31 320.5 - The colon as an energy salvage organ for children with short bowel syndrome ................................... 32 320.6 - Potential biomarkers to guide immunosuppression management in intestinal transplant recipients ............................................................................................................................................................................................... 32 320.7 - Is there a life after surgery for acute mesenteric ischemia? A retrospective study of 184 survivors . 33 320.8 - Identification of biomarkers for risk, diagnosis, and prognosis of GVHD after bowel transplantation and central role of graft resident memory T cells in pathogenesis .......................................................................... 34 320.9 - The Double-Barrel Enteroplasty: A Novel Intestinal Lengthening Procedure for Short Bowel Syndrome ............................................................................................................................................................................ 35 320.10 - "Stoma or no stoma that is the question": a single-center experience of intestinal transplantation without stoma .....................................................................................................................................................................36 350.5 - Acute Rejection Following Intestinal Transplantation in a Cohort of 442 Transplants Performed Over Nearly 25 Years: The University of Miami Experience ................................................................................................36 350.6 - The impact of circulating DSA in visceral transplant recipients without histological evidence of rejection: How should we treat or not treat? ............................................................................................................... 37 350.7 - Post-Transplant Proliferative Disorder Following Intestine Transplantation: Contemporary Single Center Experience............................................................................................................................................................. 38 360.5 - Successul implementation of remote consultation for patients recceiving home parenteral nutrition .............................................................................................................................................................................................. 38 360.6 - Long term results of a series of pediatric patients with short bowel syndrome treated at an Intestinal Failure, Rehabilitation and Transplant Program ........................................................................................ 39 360.7 - Ex vivo tumor resection and intestinal autotransplantation – a single center 10-year experience ... 40 370.5 - Post-transplant ulcerative ileitis (PTUI): risk factors and outcomes........................................................ 40 370.6 - The Role of T helper 17 cells in Severe Intestinal Transplant Rejection Renders it a Third Form of Inflammatory Bowel Disease